FLGT News and Press, Fulgent Genetics Inc. From 11/28/21

Fulgent Genetics (NASDAQ: FLGT) looks poised to significantly beat its year-end investor estimates. In this Motley Fool Live video recorded on November 15 , Motley Fool contributors Keith Speights and Brian Orelli answer a viewer question about whether this means Fulgent is ...

While large-cap stocks are usually safer, small-cap stocks are often way more exciting. If you own the right small cap, you can make a lot of money as your company becomes the large cap of tomorrow. This panel of Fool.com contributors has three small-cap COVID-19 stock ideas for intrepi...

Like many companies, Fulgent Genetics (NASDAQ: FLGT) has been labeled a "pandemic stock" by some investors. It's easy to understand why. In the most recent quarter, 82% of Fulgent's revenue came from COVID-19 tests. However, buried beneath this headline statistic is a genetic testin...

Although cases of COVID-19 in the U.S. have fallen to less than half of their numbers just two months ago, it's looking increasingly likely that there will be a long tail of demand for vaccines, boosters, and testing. Despite that, the market seems to be losing interest in COVID stocks ...

Fulgent Genetics (NASDAQ: FLGT) announced its third-quarter results on Nov. 9, 2021. In this Motley Fool Live video recorded on Nov. 10 , Motley Fool contributors Keith Speights and Brian Orelli discuss what investors should like about the company's Q3 update. ...

Fulgent has benefited tremendously from its COVID-19 testing business. As we move towards an endemic COVID era, questions on Fulgent's core NGS business starts emerging. We discuss what investors should consider on Fulgent stock moving forward. For further details see: F...

Investors worry about the demise of their insanely profitable Covid business, but they shouldn't. The epic ramp in that business put the company on the map and will deliver $1B+ in cash by the end of the year. They are using that bonanza wisely to accelerate their core NGS busines...

Image source: The Motley Fool. Fulgent Genetics, Inc. Common Stock (NASDAQ: FLGT) Q3 2021 Earnings Call Nov 09, 2021 , 4:30 p.m. ET Operator Continue reading For further details see: Fulgent Genetics, Inc. Common Stock (FLGT) Q3 2021 Earn...

Fulgent Genetics, Inc. (FLGT) Q3 2021 Earnings Conference Call November 9, 2021, 4:30 PM ET Company Participants Ming Hsieh – Chief Executive Officer Nicole Borsje – Investor Relations Paul Kim – Chief Financial Officer Larry Weiss – Chief Medical Officer Brandon P...

Fulgent Genetics (NASDAQ:FLGT): Q3 Non-GAAP EPS of $4.05 beats by $0.80; GAAP EPS of $3.93 beats by $2.36. Revenue of $227.87M (+124.0% Y/Y) beats by $20.82M. Press Release Q4 2021 Outlook: Total Revenue of approximately $189 million, Core Revenue of approximately $32 million, representing gr...